loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Tenalisib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Tenalisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rhizen Announces Data Presentations at ESMO 2022 for Its Clinical Stage Assets
    Rhizen Announces Data Presentations at ESMO 2022 for Its Clinical Stage Assets

    09 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220909005131/en

    BUSINESSWIRE
    09 Sep 2022
    Share Share
    Rhizen Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530)
    Rhizen Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530)

    13 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211013005802/en/Rhizen-Pharmaceuticals-AG-Announces-First-Patient-Dosing-in-a-Phase-II-Study-of-Tenalisib-RP6530-in-Locally-Advanced-or-Metastatic-Breast-Cancer-Patients

    BUSINESSWIRE
    13 Oct 2021
    Share Share
    Rhizen Begins Dosing in Phase II Study of Tenalisib in Breast Cancer
    Rhizen Begins Dosing in Phase II Study of Tenalisib in Breast Cancer

    13 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211013005802/en/Rhizen-Pharmaceuticals-AG-Announces-First-Patient-Dosing-in-a-Phase-II-Study-of-Tenalisib-RP6530-in-Locally-Advanced-or-Metastatic-Breast-Cancer-Patients

    BUSINESSWIRE
    13 Oct 2021
    Share Share
    Alembic Pharma share price gains as associate company enters agreement Tenalisib
    Alembic Pharma share price gains as associate company enters agreement Tenalisib

    12 Oct 2020

    // MONEYCONTROL

    https://www.moneycontrol.com/news/business/stocks/alembic-pharma-share-price-gains-as-associate-company-enters-agreement-to-develop-tenalisib-5956431.html

    MONEYCONTROL
    12 Oct 2020
    Share Share